Rare Disease vs Cardiovascular — Deal Terms Comparison

Rare Disease Median Upfront

$285M

Total: $1.6B

Cardiovascular Median Upfront

$606M

Total: $3.0B

Rare Disease Royalties

7.8%-15.6%

Tiered to 19.6%

Cardiovascular Royalties

9.4%-18.7%

Tiered to 22.7%

Model Your Deal

Market Analysis

Rare Disease and Cardiovascular represent distinct licensing landscapes with different risk-reward dynamics. Phase 2 rare disease deals carry a median total deal value of $1.6B with $285M upfront, compared to $3.0B total value and $606M upfront for cardiovascular. The differences reflect divergent clinical development timelines, regulatory pathways, and addressable market sizes.

Deal structures differ across therapeutic areas. Rare Disease deals allocate 18% to upfront and 82% to milestones, while Cardiovascular deals split 20%/80%. Development milestones are $283M for rare disease versus $537M for cardiovascular, reflecting the different clinical trial designs and approval standards in each area.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How do rare disease and cardiovascular deal terms compare?

Rare Disease Phase 2 deals average $1.6B total value ($285M upfront), while Cardiovascular deals average $3.0B ($606M upfront). The differences are driven by addressable market size, clinical development complexity, and regulatory pathway characteristics.

Which therapeutic area commands higher royalty rates: Rare Disease or Cardiovascular?

Rare Disease base royalties range from 7.8% to 15.6%, while Cardiovascular royalties range from 9.4% to 18.7%. Royalty rates reflect pricing power, competitive dynamics, and patent protection characteristics specific to each therapeutic area.

What drives the deal value differences between rare disease and cardiovascular?

Key factors include addressable patient population size, clinical trial costs and timelines, regulatory pathway complexity, pricing and reimbursement dynamics, and competitive landscape density. Rare Disease and Cardiovascular each have unique value drivers that shape deal economics.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included